Sensus Healthcare (NASDAQ:SRTS) Stock Price Passes Below 50-Day Moving Average – Here’s What Happened

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $3.74 and traded as low as $2.66. Sensus Healthcare shares last traded at $2.70, with a volume of 53,292 shares.

Analyst Ratings Changes

SRTS has been the subject of several research reports. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Wall Street Zen lowered Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a research report on Tuesday, April 21st. Alliance Global Partners initiated coverage on Sensus Healthcare in a research report on Friday, March 6th. They issued a “buy” rating and a $7.50 target price for the company. Finally, Maxim Group decreased their target price on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $6.88.

Sensus Healthcare Trading Down 4.3%

The firm has a market cap of $44.44 million, a price-to-earnings ratio of -5.74 and a beta of 1.09. The stock has a 50-day moving average of $3.74 and a 200-day moving average of $4.09.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%. The company had revenue of $3.39 million for the quarter, compared to analyst estimates of $5.32 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Opes Wealth Management LLC acquired a new position in Sensus Healthcare during the 3rd quarter valued at approximately $50,000. XTX Topco Ltd bought a new stake in Sensus Healthcare during the 4th quarter valued at $77,000. Jane Street Group LLC bought a new stake in Sensus Healthcare during the 4th quarter valued at $79,000. Mindset Wealth Management LLC raised its stake in Sensus Healthcare by 28.1% during the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock valued at $157,000 after acquiring an additional 11,000 shares in the last quarter. Finally, Ingalls & Snyder LLC bought a new stake in Sensus Healthcare during the 4th quarter valued at $219,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.